Skip to main content
Journal cover image

Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer.

Publication ,  Journal Article
Moss, HA; Perhanidis, JA; Havrilesky, LJ; Secord, AA
Published in: Gynecol Oncol
October 2021

OBJECTIVES: The clinical utility of maintenance therapy (MT) for patients with platinum-sensitive recurrent ovarian cancer has been validated in several clinical trials. We assessed "real-world" treatment patterns using an electronic health record (EHR) database. METHODS: A retrospective study of patients diagnosed with ovarian cancer between January 1, 2011 and July 31, 2019 was conducted using the US nationwide Flatiron Health (EHR)-derived de-identified database. Patients were included if they received second- or third-line (2 L or 3 L) platinum-based chemotherapy (PBCT). Information regarding biomarker status was obtained. RESULTS: 2292 patients with ovarian cancer received at least two lines of therapy. 222 patients completed PBCT on or after March 1, 2017 and had ≥2 months of active surveillance or received MT with poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPi) or bevacizumab. 46 (20%) had BRCA mutations (BRCAm), 132 (59%) had a wildtype BRCA (BRCAwt) gene, and 47 (21%) were unknown. Of patients with BRCAm, 63% received a PARPi, 17% received bevacizumab, and 20% underwent active surveillance. Of patients with BRCAwt, 40% received a PARPi, 23% received bevacizumab, and 36% underwent active surveillance. MT was more common in those with younger age and a BRCA mutation. PARPi use increased on average by 1.3% every 3 months (p = .02) with no statistically significant change in use of bevacizumab. CONCLUSIONS: In this real-world population, MT is becoming progressively more common following 2 L or 3 L PBCT regardless of biomarker status. The results provide insight into the shifting treatment patterns for patients with recurrent ovarian cancer.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Gynecol Oncol

DOI

EISSN

1095-6859

Publication Date

October 2021

Volume

163

Issue

1

Start / End Page

50 / 56

Location

United States

Related Subject Headings

  • Young Adult
  • Retrospective Studies
  • Poly(ADP-ribose) Polymerase Inhibitors
  • Platinum
  • Ovarian Neoplasms
  • Oncology & Carcinogenesis
  • Neoplasm Recurrence, Local
  • Mutation
  • Middle Aged
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Moss, H. A., Perhanidis, J. A., Havrilesky, L. J., & Secord, A. A. (2021). Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer. Gynecol Oncol, 163(1), 50–56. https://doi.org/10.1016/j.ygyno.2021.07.026
Moss, Haley A., Jessica A. Perhanidis, Laura J. Havrilesky, and Angeles Alvarez Secord. “Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer.Gynecol Oncol 163, no. 1 (October 2021): 50–56. https://doi.org/10.1016/j.ygyno.2021.07.026.
Moss HA, Perhanidis JA, Havrilesky LJ, Secord AA. Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer. Gynecol Oncol. 2021 Oct;163(1):50–6.
Moss, Haley A., et al. “Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer.Gynecol Oncol, vol. 163, no. 1, Oct. 2021, pp. 50–56. Pubmed, doi:10.1016/j.ygyno.2021.07.026.
Moss HA, Perhanidis JA, Havrilesky LJ, Secord AA. Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer. Gynecol Oncol. 2021 Oct;163(1):50–56.
Journal cover image

Published In

Gynecol Oncol

DOI

EISSN

1095-6859

Publication Date

October 2021

Volume

163

Issue

1

Start / End Page

50 / 56

Location

United States

Related Subject Headings

  • Young Adult
  • Retrospective Studies
  • Poly(ADP-ribose) Polymerase Inhibitors
  • Platinum
  • Ovarian Neoplasms
  • Oncology & Carcinogenesis
  • Neoplasm Recurrence, Local
  • Mutation
  • Middle Aged
  • Humans